What are the indications, dosing regimens, contraindications, and safety precautions for levofloxacin (Levaquin)?

Levofloxacin (Levaquin): Clinical Overview

Levofloxacin is a broad-spectrum fluoroquinolone antibiotic indicated for treating various bacterial infections in adults, with specific FDA-approved indications including respiratory tract infections, urinary tract infections, skin infections, and inhalational anthrax, but it should be reserved for situations where alternative treatments are not suitable due to serious safety concerns including tendon rupture, peripheral neuropathy, and CNS effects. 1

FDA-Approved Indications

Respiratory Tract Infections

• Nosocomial pneumonia: Effective against methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, and other gram-negative pathogens; combination therapy with an antipseudomonal β-lactam is recommended when P. aeruginosa is suspected 1
• Community-acquired pneumonia (CAP): Two regimens available:
  • Standard: 500 mg daily for 7-14 days for infections including multidrug-resistant Streptococcus pneumoniae (MDRSP) 1
  • High-dose short-course: 750 mg daily for 5 days for non-MDRSP strains 1, 2
• Acute bacterial sinusitis: 500 mg daily for 5 days or 10-14 days 1
• Acute bacterial exacerbation of chronic bronchitis: 500 mg daily 1

Urinary Tract Infections

• Complicated UTI: 750 mg daily for 5 days or 250 mg daily for 10 days 1
• Acute pyelonephritis: 750 mg daily for 5 days or 250 mg daily for 10 days 1
• Uncomplicated UTI: 250 mg daily for 3 days 1
• Chronic bacterial prostatitis: 500 mg daily for 28 days 1

Skin and Soft Tissue Infections

• Complicated infections: 750 mg daily for 7-14 days 1
• Uncomplicated infections: 500 mg daily for 7-10 days 1

Bioterrorism-Related Indications

• Inhalational anthrax (post-exposure): 500 mg daily for 60 days in adults; approved for pediatric patients ≥6 months 1
• Plague: Approved for treatment and prophylaxis in pediatric patients ≥6 months 1

Dosing Regimens

Adult Dosing

• Standard dose: 250-500 mg once daily 3
• High-dose regimen: 750 mg once daily for severe infections 3, 1
• Drug-resistant tuberculosis: 500-1,000 mg daily (not a first-line agent) 3

Pediatric Dosing

• Generally not recommended for routine use in children due to concerns about cartilage and bone growth effects 3, 1
• Exceptions: Approved for children ≥6 months for inhalational anthrax and plague 1
• MDR tuberculosis: May be considered despite lack of approval, though optimal dose unknown 3
• Dosing when used: 10 mg/kg twice daily for children <5 years; 10 mg/kg once daily (maximum 500 mg) for children ≥5 years 1

Renal Dose Adjustments

• Creatinine clearance <50 mL/min: Reduce to 750-1,000 mg three times weekly 3
• Primary renal clearance: 80% eliminated by kidneys 3
• Not removed by hemodialysis: No supplemental dosing needed post-dialysis 3

Hepatic Impairment

• No dose adjustment required: Drug levels unaffected by hepatic disease 3
• Use with caution in severe liver disease as with all medications 3

Contraindications and Major Precautions

Absolute Contraindications

• Pregnancy: Avoid due to teratogenic effects and cartilage toxicity in animal studies 3, 1
• Known hypersensitivity to levofloxacin or other fluoroquinolones 1

Black Box Warnings and Serious Risks

• Tendon rupture: Increased risk in elderly patients, especially those on corticosteroids; can occur during or months after therapy 1
• Peripheral neuropathy: May be permanent; discontinue immediately if symptoms develop 1
• CNS effects: Seizures, increased intracranial pressure, tremors, confusion 1
• Myasthenia gravis exacerbation: Avoid use in patients with known myasthenia gravis 1

Special Populations

• Elderly patients: Higher risk for tendon disorders and severe adverse events, particularly when combined with corticosteroids 1
• Nursing mothers: Presumed to be excreted in breast milk; discontinue nursing or drug 1
• Pediatric use: Long-term musculoskeletal disorders occurred more frequently in levofloxacin-treated children (arthralgia most common), though most resolved without sequelae 1

Common Adverse Effects

Gastrointestinal

• Nausea and bloating: 0.5-1.8% of patients 3
• Diarrhea: Common in clinical trials 1

Neurologic

• Dizziness, insomnia, tremulousness, headache: 0.5% of patients 3

Dermatologic

• Rash, pruritus, photosensitivity: 0.2-0.4% of patients 3

Critical Drug Interactions

Absorption Interference

• Antacids and divalent cations (calcium, magnesium, aluminum, iron, zinc): Markedly decrease fluoroquinolone absorption 3
• Timing requirement: Do not administer levofloxacin within 2 hours of these medications 3

QTc Prolongation

• Avoid moxifloxacin for UTI treatment due to uncertain urinary concentrations 3
• Levofloxacin preferred over moxifloxacin in drug-resistant TB due to less QTc prolongation 3

Clinical Considerations

Resistance Patterns

• Cross-resistance: Demonstrated among ciprofloxacin, ofloxacin, and levofloxacin; presumed class effect 3
• Not first-line for drug-susceptible TB: Reserve for drug-resistant cases or intolerance to first-line agents 3
• P. aeruginosa resistance: May develop rapidly during treatment; periodic culture and susceptibility testing recommended 1

Formulations and Bioavailability

• Tablets: 250 mg, 500 mg, 750 mg 3
• Intravenous solution: 500 mg 3
• Oral bioequivalence: Oral formulation is bioequivalent to IV; seamless transition between routes possible 2, 4

CNS Penetration

• CSF concentration: 16-20% of serum levels with standard dosing 3

Duration of Therapy

• CAP with prompt resolution: 7 days recommended 3
• CAP with delayed response: 10-14 days recommended 3
• High-dose short-course: 750 mg for 5 days may be considered for non-severely ill CA-UTI patients 3
• Catheter-associated UTI in women ≥65 years: 3-day regimen acceptable after catheter removal if no upper tract symptoms 3

Surgical Prophylaxis

• Single dose: 500 mg PO for urologic procedures 3
• Orthopedic patients with joint replacements: 500 mg ciprofloxacin or levofloxacin for high-risk patients meeting specific criteria 3

Common Pitfalls to Avoid

• Do not use as empiric monotherapy for nosocomial pneumonia when P. aeruginosa is suspected without adding an antipseudomonal β-lactam 1
• Avoid routine use in children except for life-threatening infections (anthrax, plague, MDR-TB) where benefits outweigh cartilage toxicity risks 3, 1
• Do not prescribe with antacids or multivitamins containing divalent cations without proper timing separation 3
• Discontinue immediately if patient develops tendon pain, peripheral neuropathy symptoms, or CNS effects 1
• Reserve for appropriate indications: Given resistance concerns and serious adverse effects, use only when culture data support use or when alternative agents are contraindicated 1, 5